Clarity Pharmaceuticals Ltd. (AU:CU6)
ASX:CU6
Want to see AU:CU6 full AI Analyst Report?
CU6 Stock Chart & Stats
AU$3.13
-AU$0.24(-5.69%)
At close: 4:00 PM EST
AU$3.13
-AU$0.24(-5.69%)
Day’s Range― - ―
52-Week RangeAU$1.84 - AU$5.87
Previous CloseN/A
Volume1.66M
Average Volume (3M)3.27M
Market Cap
AU$1.10B
Enterprise ValueAU$834.69M
Total Cash (Recent Filing)AU$226.25M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta2.44
Next Earnings
Aug 26, 2026EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.15
Shares Outstanding372,258,100
10 Day Avg. Volume4,406,737
30 Day Avg. Volume3,266,690
Financial Highlights & Ratios
PEG Ratio-0.37
Price to Book (P/B)8.84
Price to Sales (P/S)84.33
P/FCF Ratio-14.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$7.46Price Target Upside138.18% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.3
Revenue Forecast (FY)AU$4.33M
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetZero reported debt materially reduces financial risk and eliminates interest burden, giving management structural flexibility to fund R&D and clinical programs via equity or partnerships. For a cash-burning biotech, a debt-free position lowers default risk and preserves optionality over months.
Long-run Revenue Growth TrendSustained multi-year revenue growth indicates the company has been building commercial traction or research partnerships prior to recent setbacks. This durable top-line progress supports the view that underlying demand or licensing activity exists and can underpin recovery if expense discipline or funding enable continued execution.
High Gross MarginsNear-100% gross margins reflect the structural economics of radiopharmaceutical products and suggest attractive per-unit profitability once fixed R&D and SG&A are managed. High product-level margins improve potential returns on commercialization and enable scalable earnings leverage as revenues grow.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flow creates a structural funding requirement: the company must repeatedly access equity or partners to sustain clinical programs. Over 2–6 months this raises dilution risk, forces program prioritization, and limits ability to self-fund multiple development pathways.
Widening LossesSharply increasing net losses erode retained capital and constrain internal financing for trials and commercialization. Persistently negative EBIT undermines reinvestment capacity and makes the business reliant on external capital or partnerships, slowing long-term progress toward sustainable profitability.
Declining Equity BaseA meaningful drop in shareholders' equity reflects cumulative losses and potential dilution, weakening the balance-sheet buffer. This structural erosion limits the firm's ability to absorb setbacks, may raise cost of future financing, and reduces downside protection for investors over the coming months.
Clarity Pharmaceuticals Ltd. News
CU6 FAQ
What was Clarity Pharmaceuticals Ltd.’s price range in the past 12 months?
Clarity Pharmaceuticals Ltd. lowest share price was AU$1.84 and its highest was AU$5.87 in the past 12 months.
What is Clarity Pharmaceuticals Ltd.’s market cap?
Clarity Pharmaceuticals Ltd.’s market cap is AU$1.10B.
When is Clarity Pharmaceuticals Ltd.’s upcoming earnings report date?
Clarity Pharmaceuticals Ltd.’s upcoming earnings report date is Aug 26, 2026 which is in 123 days.
How were Clarity Pharmaceuticals Ltd.’s earnings last quarter?
Clarity Pharmaceuticals Ltd. released its earnings results on Feb 26, 2026. The company reported -AU$0.153 earnings per share for the quarter, missing the consensus estimate of -AU$0.083 by -AU$0.07.
Is Clarity Pharmaceuticals Ltd. overvalued?
According to Wall Street analysts Clarity Pharmaceuticals Ltd.’s price is currently Undervalued.
Does Clarity Pharmaceuticals Ltd. pay dividends?
Clarity Pharmaceuticals Ltd. does not currently pay dividends.
What is Clarity Pharmaceuticals Ltd.’s EPS estimate?
Clarity Pharmaceuticals Ltd.’s EPS estimate is -0.16.
How many shares outstanding does Clarity Pharmaceuticals Ltd. have?
Clarity Pharmaceuticals Ltd. has 372,258,100 shares outstanding.
What happened to Clarity Pharmaceuticals Ltd.’s price movement after its last earnings report?
Clarity Pharmaceuticals Ltd. reported an EPS of -AU$0.153 in its last earnings report, missing expectations of -AU$0.083. Following the earnings report the stock price went up 0.278%.
Which hedge fund is a major shareholder of Clarity Pharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in AU:CU6
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Clarity Pharmaceuticals Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$7.46 (138.18% Upside)
AU$7.46 (138.18% Upside)
Blogger Sentiment
Bullish
AU:CU6 Sentiment 89%
Sector Average 72%
Sector Average 72%
Insider Transactions
Sold Shares
Worth AU$1.1M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-25.03%
12-Months-Change
Fundamentals
Return on Equity
-59.59%
Trailing 12-Months
Asset Growth
86.54%
Trailing 12-Months
Company Description
Clarity Pharmaceuticals Ltd.
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. The company has collaboration with GU Research Network for an investigator initiated Trial X-Calibur, using 64Cu-SAR-bisPSMA in known or suspected prostate cancer. Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia.
CU6 Stock 12 Month Forecast
Average Price Target
AU$7.46
▲(138.18% Upside)
Technical Analysis
Clinuvel Pharmaceuticals
―
Immutep Ltd
―
Telix Pharmaceuticals
―
PYC Therapeutics Limited
―
Botanix Pharmaceuticals Limited
―
Options Prices
Currently, No data available
---